Evotec subsidiary moves JST-018 orthopoxvirus antibodies into Phase 1
First-in-human Phase 1 study has started for investigational orthopoxvirus antibodies developed under the U.S. Department of War Accelerated Antibodies Program, supporting biodefense countermeasures.
A first-in-human Phase 1 study has been initiated for investigational antibodies targeting orthopoxviruses developed under the U.S. Department of War Accelerated Antibodies Program. The program is intended to support countermeasures against orthopoxviruses, a high-priority biological threat family that includes the viruses responsible for smallpox. The work also covers integrated process development, regulatory submission and manufacturing of clinical trial material at the J.POD® Redmond facility.
The company said the effort is designed to show a scalable model for development and continuous manufacturing for biodefense preparedness.